PepGen Inc. announced the appointment of Kasra Kasraian, PhD, as its new Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.
Dr. Kasraian's background includes significant roles at bluebird bio, where he served as Senior Vice President, Quality, Regulatory Affairs, and CMC Sciences, and previously as Senior Vice President, Technical Development and Operations. In these roles, he played a central part in the approval and launch of three gene therapy products.
This appointment is expected to be instrumental as PepGen progresses its clinical programs through mid-stage development and beyond. His expertise in advancing therapies for rare genetic disorders and navigating manufacturing and regulatory landscapes will support the company's goal of delivering transformative therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.